Pre-merger, Sonnet leveraged a fully human single-chain antibody fragment designed to bind human serum albumin and transport large-molecule therapies toward tumor and lymphatic tissue, supporting constructs that include cytokines, peptides, antibodies and vaccines. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. As of the merger, the company is now focused on cryptocurrency holdings rather than drug development.
Cyborg Score Rationale
Sonnet Biotherapeutics Holdings (SONN) has a market cap of $8.6M as of June 01, 2026. The company experienced a dramatic pivot away from oncology drug development following its December 2025 merger with a crypto-focused entity, representing extreme strategic risk for biotech investors.
Top Insights
Company merged with Hyperliquid Strategies in December 2025, transforming from clinical-stage oncology biotech to crypto-treasury holding company
Original FHAB platform targeted immunotherapeutics with pipeline including SON-1010 for solid tumors and ovarian cancer
Market cap collapsed to ~$8.6M as of June 2026, down from 52-week high of $19.30
Pre-merger business strategy focused on albumin-binding platform for bispecific therapeutics in oncology and immune disorders